The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BSH 2017 | What’s next for Richter’s syndrome?

Name: What’s next for Richter’s syndrome?
Uploaded: 2017-03-27T00:00:00.000Z
Duration: 56 s
Description: Barbara Eichhorst, MD, from the University of Cologne, Cologne, Germany, discusses the challenges of treating Richter’s syndrome at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She highlights the need for clinical trials in this disease despite the small number of patients, and speaks about drug types which may be effective in this patient group.

Barbara Eichhorst • 27 Mar 2017

BSH 2017

Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Checkpoint inhibitors

Barbara Eichhorst, MD, from the University of Cologne, Cologne, Germany, discusses the challenges of treating Richter’s syndrome at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. She highlights the need for clinical trials in this disease despite the small number of patients, and speaks about drug types which may be effective in this patient group.